NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-14
A Clinical Trial to Assess Tamoxifen in Patients With Primary Breast Cancer and Negative Axillary Nodes Whose Tumors are Positive for Estrogen Receptors

Specific Aims
To determine whether tamoxifen is more effective than no treatment with respect to disease-free survival and survival in patients with negative axillary nodes and estrogen-receptor-positive tumors. (See Schema 1)

In conjunction with Protocol B-13, this protocol will also permit evaluation of treatment failure and survival in untreated patients relative to their hormone-receptor levels.

Protocol B-14 was originally designed to treat patients for a total of 2 years but was subsequently modified to maintain treatment through 5 years. In 1987, an extension of B-14 was initiated to evaluate the effectiveness of tamoxifen for 10 years; specifically, to determine whether an additional 5 years of tamoxifen therapy is effective in prolonging disease-free survival and survival in patients with negative nodes and estrogen-receptor-positive tumors. Patients who complete the initially assigned 5 years of tamoxifen therapy are rerandomized to 5 additional years of either tamoxifen or placebo. (See Schema 2)

Randomization for the original protocol objectives was terminated January 25, 1988. From that date until October 17, 1988, all eligible patients were registered to tamoxifen in an effort to enhance the pool of patients eligible for rerandomization at 5 years. At that time protocols B-19 and B-20 opened.